DENND2D downregulation or silencing, frequently driven by promoter hypermethylation, has been implicated in the development of non-small cell lung cancer (NSCLC) [29], esophageal squamous cell carcinoma [30], hepatocellular carcinoma [8], and gastric cancer [10]. Here, DENND2D is linked to hepatocellular carcinoma.